Search

everythinglearnresearchcommunity

for

Search:↓

Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).

This user has been taking finasteride for several years and recently added topical minoxidil to their regimen, specifically targeting the area of hair loss. They are wondering if this was a wise course of action.

CosmeRNA, a new hair loss treatment, is expected to release soon and may become part of the "big three" treatments alongside finasteride and minoxidil. It works differently from finasteride by targeting androgen receptors in hair follicles, potentially offering fewer side effects.

The conclusion of the conversation is that the user "Shakalakaplaka" shares their comprehensive hair loss regimen, which includes various treatments targeting different pathways such as DHT, inflammation, fibrosis, immune system, testosterone, gut problems, and scalp health. The effectiveness of the regimen is not confirmed, and some users express skepticism or request before and after pictures for credibility.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.

The conversation discusses the potential of GT20029 to stop hair loss and possibly regrow hair, considering the body's regenerative abilities. No specific treatments were mentioned due to the original post being removed.

Pyrilitamide (KX-826) did not show significant improvement in hair count compared to placebo after 6 months. It's unclear if it can maintain hair at baseline.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

A user is planning to get extensive blood tests before starting Finasteride and is seeking advice on which tests are necessary. They are concerned about the cost and potential redundancy of some tests.

The conversation is about whether Saw Palmetto, which has similar but less potent effects to Finasteride, could cause the same side effects due to lowering DHT levels. The user is considering oral Saw Palmetto as an alternative to Finasteride for hair loss treatment.

Finasteride prevents further hair loss by blocking DHT, while minoxidil stimulates hair growth by prolonging the active phase of hair follicles. Stopping minoxidil can lead to loss of regrown hair because finasteride does not address the same growth mechanism.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

A 26-year-old male is experiencing hair loss and is interested in Botox scalp injections as a treatment, preferring it over finasteride due to fewer hormonal impacts. He seeks recommendations for US doctors offering this treatment and feedback from those with experience.

Dutasteride at 2.5mg is considered a potential hair loss cure due to its DHT-blocking ability, but there are concerns about side effects and individual responses. Minoxidil, finasteride, and RU58841 are also discussed, with mixed opinions on their effectiveness and safety.

The conversation discusses the potential use of HMI 115 for hair loss and whether it could replace or be used alongside finasteride, minoxidil, and RU58841. The user is experiencing scalp inflammation and continued hair shedding despite using finasteride for 8 years.

A user shared their hair loss treatment routine, which includes oral and topical Minoxidil, dermarolling, Keto shampoo, multivitamins, Biotin, oils, protein intake, and water. Another user suggested adding finasteride and continuing the routine for 6-12 months.

The user is experiencing intense hair shedding all over the scalp after applying pyrilutamide to the hairline and taking oral castor oil. They are also using topical finasteride and latanoprost, but are unsure which treatment is causing the shedding.

KX-826 initially improves hair growth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.

The user reported significant hair regrowth using a topical treatment of 0.3% finasteride and 6% minoxidil, with noticeable progress in five months. The treatment is applied once daily, and the user experienced some initial shedding but no side effects.

Lichen Planopilaris (LPP) is an autoimmune condition causing permanent hair loss and fibrosis, often misdiagnosed. Treatments include pioglitazone, topical corticosteroids, anti-inflammatory medication, and Jak inhibitors.

A user wonders if she should tell her boyfriend about his hair loss. Responses suggest telling him gently and discussing treatments like Minoxidil and finasteride.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.

Oral minoxidil may deplete collagen, potentially causing skin aging. Users discuss whether taking collagen supplements can counteract this effect.

A user shared their 3-month progress using Hims topical spray containing minoxidil and finasteride for hair loss, noting some improvement and stopping dermarolling. They hope for continued growth despite noticing some hair shedding.

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.